Boehringer Ingelheim GmbH priced its new treatment for a deadly lung-scarring disease at $96,000 a year, just higher than Roche Holding AG’s (ROG) competing product. Read More
Some patients are paying sky-high prices for ‘specialty medications’ when cheaper options exist, a team of researchers has found. Read More
Pricey new hepatitis C drugs, such as Gilead Sciences Inc.'s Sovaldi, may make financial sense to give to give to prisoners, one of the main groups infected with the liver-damaging virus, according to a team of Stanford University researchers. Read More
Harvoni’s launch brought new howls about price gouging from insurers and a broad coalition of health care groups. They warn that the drugs, no matter how revolutionary, are ultimately unaffordable given the estimated 3 million Americans who may be infected with hepatitis C. Read More
According to a recent survey from the Kaiser Family Foundation, almost every state Medicaid plan is concerned about the rising cost of specialty drugs -- specifically Sovaldi. Sovaldi is a hepatitis c drug from Gilead Sciences which costs $1,000 a pill, or $84,000 for a 12-week treatment—prices which the plans have balked at. Read More
On the day that Gilead introduced its new $94,500 hepatitis C drug, Harvoni, Gilead Vice President of Investor Relations Patrick O'Brien went into full spin mode, telling Politico (subscription required) that Harvoni is a bargain compared to Gilead's other hep C drug, the $84,000 Sovaldi. Read More
Tennessee Medicaid Director Darin Gordon said today that his state has a $700… Read More
Now that the FDA has approved the Harvoni treatment from Gilead Sciencesand a $94,500 price for a 12-week regimen has been established, attention is turning toward AbbVie and the steps the big drug maker must take to win market share. Read More
Perhaps no company has done as much as Gilead to propel the issue of high drug prices onto center stage or to lay bare the pharmaceutical industry’s approach to pricing new drugs. Read More
How might state Medicaid programs cope with a new and equally expensive hepatitis C treatment from Gilead Sciences. Read More
The Department of Veterans Affairs, still reeling from a scandal over the negligent treatment of veterans seeking medical care that may have contributed to some deaths, has a new problem on its hands. Read More
Consumers keep price top of mind when they purchase prescription drugs and they’re unafraid to buy against the big labels, a new Morning Consult poll found. Read More